2.1
Cemiplimab (Libtayo, Regeneron) is indicated for 'the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy'.
2 Information about cemiplimab
Marketing authorisation indication
Dosage in the marketing authorisation
2.2
The dosage schedule is available in the summary of product characteristics for cemiplimab.
Price
2.3
The list price for cemiplimab is £4,650 per 350‑mg vial (excluding VAT, BNF online accessed June 2026).
2.4
The company has a commercial arrangement. This makes cemiplimab available to the NHS with a discount. The size of the discount is commercial in confidence.
Sustainability
2.5
For information, the Carbon Reduction Plan for UK carbon emissions is published on the Regeneron webpage on transparency and policies.